A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
about
Contemporary approaches for imaging skeletal metastasisUse of a digital phantom developed by QIBA for harmonizing SUVs obtained from the state-of-the-art SPECT/CT systems: a multicenter study.Analysis of regional bone scan index measurements for the survival of patients with prostate cancer.Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy.Prognostic Utility of PET in Prostate Cancer.Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.Evaluation of bone scan index change over time on automated calculation in bone scintigraphy.Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancerPrognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment.The relationship between skeletal-related events and bone scan index for the treatment of bone metastasis with breast cancer patients.A novel statistical analysis method to improve the detection of hepatic foci of (111)In-octreotide in SPECT/CT imaging.Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy.Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.Translational Molecular Imaging of Prostate Cancer.Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project.3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancerTMPRSS2-ERG fusion promotes prostate cancer metastases in bone.Validation and clinical utility of prostate cancer biomarkers.Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial.Palliative Care Research--A Systematic Review of foci, designs and methods of research conducted in Sweden between 2007 and 2012.Imaging and evaluation of patients with high-risk prostate cancer.Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT.Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer.Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer.Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer.Prospective evaluation of computer-assisted analysis of skeletal lesions for the staging of prostate cancerInfluence of the Different Primary Cancers and Different Types of Bone Metastasis on the Lesion-based Artificial Neural Network Value Calculated by a Computer-aided Diagnostic System, BONENAVI, on Bone Scintigraphy Images.Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index.Automated Bone Scan Index as Predictors of Survival in Prostate CancerAnalytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features.Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis.Quantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer.Relationship between tumor volume and quantitative values calculated using two-dimensional bone scan images.Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.Diagnostic performance of bone scintigraphy analyzed by three artificial neural network systems.
P2860
Q26798170-C82C940E-8A99-4BE5-8E04-ABB60D4FC28AQ33822271-1713E014-B98A-4EDB-8C40-046DFC1CC1C1Q33928075-6016E1EE-BA70-49F6-9E5B-E43D918C7CCEQ34383010-937FFEAF-1316-42E6-83B1-BE4ACBBA102EQ35244433-4B32EEDD-CD65-49A8-9234-D846E1C0D3A3Q35582133-227D783E-F33B-4911-B6DE-E763D7492BA4Q35776541-6DD65BB6-1444-47B4-9CDF-4A31A2CBA536Q35925260-C23E8450-E4D2-407F-B67F-9DAD727E150CQ35929058-BCA48442-004A-410F-95D8-9847DE0006E7Q36062163-6B88BBC2-0908-4503-B244-20E0753482FEQ36153864-63DA9F31-85B6-4877-8303-B15478F6BF1FQ36480036-C5A21F6E-ED35-4C65-9012-351FA10C6756Q36604585-DE7566DF-6BC0-4D8A-9155-B57ABEF677D2Q36670075-E44C56EF-D2FA-4375-889D-B2BEE3E00899Q37244969-7083FC3D-E3FF-4029-B48E-8432D0E35FA8Q37261280-217C3DB6-BD31-4CFC-B895-0E4F5D2DDBE5Q37425136-5A8BCF4F-73F7-43A8-A9EA-B9CA98795E81Q37647591-F59A741A-BED7-4555-BBB9-594CDE4EF5D5Q37706996-05023934-A672-4564-BFEF-904B347590C2Q38086420-19A449A5-CFA7-4B82-85A9-9B7BE99CE57FQ38373645-BC01A123-C49A-47AF-B077-C8D1CB2A22AAQ38550346-A4A07A97-2AC9-44F3-855F-5830BD67344FQ38611187-A4659326-8E4A-4C75-8A30-574ABDFF1F24Q38652008-944641FC-A1F0-4462-BA9D-E6D349AB2C20Q38749882-37922858-D34B-4A7B-90E3-82BF98D13136Q38766102-8B3A3DE5-86AE-434F-B85A-8260D698084DQ39310595-4572AC62-4440-428E-977D-8D2B92B15455Q39337696-4816D8E0-F04C-4BCC-94E3-DCBEF61AC7EDQ40977755-EDB9DF1F-792A-4CEE-92A2-440164B6916DQ41026898-1BBB2CF4-F506-4A36-9040-6CE290FCB22EQ42026562-A8C2115C-7895-4652-A611-8B224C0DF88BQ42376456-46B2C957-0988-4882-BB39-D7E9A08EDCF7Q42376623-09E6EC7D-540C-458C-9204-186CCA95AEBFQ42690512-6004A21A-CD5B-45D6-B9C3-9AF33C5EB1DEQ43663413-4BAD56E7-3D24-477B-A211-836A10A472EEQ48231085-29F7C5B9-06E2-4BCF-8CDC-8384DA386056Q49566787-316FBB87-C9AF-485A-BB9B-B8E41D5F56A5Q50856991-4804F068-94EB-43F1-9352-91854B5EF7FAQ50926263-26203654-BF9C-4652-BE56-8DA43F126FCDQ51019883-41794E8E-9A13-4CAA-9F36-D18F5BE2129C
P2860
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A novel automated platform for ...... nts using the Bone Scan Index.
@ast
A novel automated platform for ...... nts using the Bone Scan Index.
@en
type
label
A novel automated platform for ...... nts using the Bone Scan Index.
@ast
A novel automated platform for ...... nts using the Bone Scan Index.
@en
prefLabel
A novel automated platform for ...... nts using the Bone Scan Index.
@ast
A novel automated platform for ...... nts using the Bone Scan Index.
@en
P2093
P2860
P50
P1433
P1476
A novel automated platform for ...... ents using the Bone Scan Index
@en
P2093
Anders Bjartell
Caroline Savage
Howard I Scher
Jens Richter
Josef J Fox
Karl Sjöstrand
Lars Edenbrandt
Madis Suurküla
P2860
P356
10.1016/J.EURURO.2012.01.037
P407
P577
2012-01-27T00:00:00Z